Lv51
1330 积分 2025-08-05 加入
Abstract 2928: Evaluating Cks1-Skp2 interface as an effective therapeutic target for RB1-deficient metastatic castration-resistant prostate cancer (mCRPC)
2天前
已关闭
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
3天前
已完结
Silencing of the S-Phase Kinase-Associated Protein 2 Gene (SKP2) Inhibits Proliferation and Migration of Hepatocellular Carcinoma Cells
4天前
已完结
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
25天前
已完结
Abstract LB318: SB-4826, a first-in-class oral, covalent inhibitor of SUMO E1 that induces IFN signaling and inhibits tumor growth as monotherapy and in combination with immune checkpoint blockade
27天前
已关闭
SUMO1 degrader extends mouse survival
1个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
2个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
2个月前
已完结
Discovery and In Vivo Exploration of 1,3,4-Oxadiazole and α-Fluoroacrylate Containing IL-17 Inhibitors
2个月前
已完结
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
2个月前
已完结
皖公网安备34019202002308
